Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Newron Pharmaceuticals
Biotech
Eisai pays $46M for Japan rights to Newron's schizophrenia med
Newron has secured 44 million euros in upfront cash from an Eisai subsidiary for select Asia rights to its add-on schizophrenia treatment.
James Waldron
Dec 13, 2024 8:37am
Newron schizophrenia add-on improves positive, negative symptoms
Apr 30, 2024 9:13am
Cerevel swaps CEO—Chutes & Ladders
May 5, 2023 9:30am
Newron's schizophrenia data boost chances of historic approval
Feb 16, 2023 8:30am
Newron ditches sarizotan program after pivotal trial flop
May 4, 2020 7:50am
Newron delays pivotal schizophrenia trials amid safety fears
May 28, 2019 7:22am
